Novel molecular insights and new therapeutic strategies in osteosarcoma

go back to reference Unni KK. Dahlin’s bone tumors: general aspects and data on 11,087 cases. 5. Philadelphia: Lippincott-Raven; 1996. p. 143–83. Unni KK. Dahlin’s bone tumors: general aspects and data on 11,087 cases. 5. Philadelphia: Lippincott-Raven; 1996. p. 143–83.

go back to reference Raymond AK. Conventional OS. Lyon: IARC Press; 2002. Raymond AK. Conventional OS. Lyon: IARC Press; 2002.

go back to reference Isakoff MS, Bielack SS, Meltzer P, Gorlick ROS. Current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–35.PubMedPubMedCentralCrossRef Isakoff MS, Bielack SS, Meltzer P, Gorlick ROS. Current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–35.PubMedPubMedCentralCrossRef

go back to reference Yan GN, Lv YF, Guo QN. Advances in OS stem cell research and opportunities for novel therapeutic targets. Cancer Lett. 2016;370(2):268–74.PubMedCrossRef Yan GN, Lv YF, Guo QN. Advances in OS stem cell research and opportunities for novel therapeutic targets. Cancer Lett. 2016;370(2):268–74.PubMedCrossRef

go back to reference Unni KK, Inwards CY. Dahlin’s bone tumors: general aspects and data on 10,165 cases. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. Unni KK, Inwards CY. Dahlin’s bone tumors: general aspects and data on 10,165 cases. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2009.

go back to reference Rosenberg AE, Cleton-Jansen AM, de Pinieux G. Conventional OS. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: International Agency for Research on Cancer; 2013. p. 282–8. Rosenberg AE, Cleton-Jansen AM, de Pinieux G. Conventional OS. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: International Agency for Research on Cancer; 2013. p. 282–8.

go back to reference Federman N, Bernthal N, Eiber FC, Tap WD. The multidisciplinary management of OS. Curr Treat Options Oncol. 2009;10:82–93.PubMedCrossRef Federman N, Bernthal N, Eiber FC, Tap WD. The multidisciplinary management of OS. Curr Treat Options Oncol. 2009;10:82–93.PubMedCrossRef

go back to reference Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422–41.CrossRefPubMed Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422–41.CrossRefPubMed

go back to reference Bramer JA, Van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity OS: a systematic review. Eur J Surg Oncol. 2009;35:1030–6.PubMedCrossRef Bramer JA, Van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity OS: a systematic review. Eur J Surg Oncol. 2009;35:1030–6.PubMedCrossRef

go back to reference Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, González MV, Baldini N, Garcia-Castro J, Rodriguez R. Osteosarcoma: cells-of-origin, cancer stem cells, and targeted therapies. Stem Cells Int. 2016;2016:3631764.PubMedPubMedCentralCrossRef Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, González MV, Baldini N, Garcia-Castro J, Rodriguez R. Osteosarcoma: cells-of-origin, cancer stem cells, and targeted therapies. Stem Cells Int. 2016;2016:3631764.PubMedPubMedCentralCrossRef

go back to reference Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR. A meta-analysis of OS outcomes in the modern medical era. Sarcoma. 2012;2012:10.CrossRef Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR. A meta-analysis of OS outcomes in the modern medical era. Sarcoma. 2012;2012:10.CrossRef

go back to reference Tang N, Song WX, Luo J, Haydon RC, He TC. OS development and stem cell differentiation. Clin Orthop Relat Res. 2008;466:2114–30.PubMedPubMedCentralCrossRef Tang N, Song WX, Luo J, Haydon RC, He TC. OS development and stem cell differentiation. Clin Orthop Relat Res. 2008;466:2114–30.PubMedPubMedCentralCrossRef

go back to reference Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, Hogendoorn. OS originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol. 2009;219:294–305.PubMedCrossRef Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, Hogendoorn. OS originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol. 2009;219:294–305.PubMedCrossRef

go back to reference Basu-Roy U, Basilico C, Mansukhani A. Perspectives on cancer stem cells in OS. Cancer Lett. 2013;338:158–67.PubMedCrossRef Basu-Roy U, Basilico C, Mansukhani A. Perspectives on cancer stem cells in OS. Cancer Lett. 2013;338:158–67.PubMedCrossRef

go back to reference Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol. 2013;61:14–25. https://doi.org/10.1002/0471141755.ph1425s61.CrossRef Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol. 2013;61:14–25. https://​doi.​org/​10.​1002/​0471141755.​ph1425s61.CrossRef

go back to reference Yu XZ, Lin YJ, Yan X, Tian Q, Li L, Lin EH. CD133, stem cells, and cancer stem cells: myth or reality? Curr Colorectal Cancer Rep. 2011;7(4):253–9.PubMedPubMedCentralCrossRef Yu XZ, Lin YJ, Yan X, Tian Q, Li L, Lin EH. CD133, stem cells, and cancer stem cells: myth or reality? Curr Colorectal Cancer Rep. 2011;7(4):253–9.PubMedPubMedCentralCrossRef

go back to reference Matsui WH. Cancer stem cell signaling pathways. Medicine. 2016;95:S8–19.PubMedPubMedCentralCrossRef Matsui WH. Cancer stem cell signaling pathways. Medicine. 2016;95:S8–19.PubMedPubMedCentralCrossRef

go back to reference Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013;34:732–40.PubMedPubMedCentralCrossRef Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013;34:732–40.PubMedPubMedCentralCrossRef

go back to reference Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. Semin Oncol. 2015;42:S3–17.PubMedCrossRef Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. Semin Oncol. 2015;42:S3–17.PubMedCrossRef

go back to reference Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002–12.PubMed Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002–12.PubMed

go back to reference Fargeas CA, Corbeil D, Huttner WB. AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells. 2003;21:506–8.PubMedCrossRef Fargeas CA, Corbeil D, Huttner WB. AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells. 2003;21:506–8.PubMedCrossRef

go back to reference Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li JM. CD133 expression in OS and derivation of CD133+ cells. Mol Med Rep. 2013;7(2):577–84.PubMedCrossRef Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li JM. CD133 expression in OS and derivation of CD133⁺ cells. Mol Med Rep. 2013;7(2):577–84.PubMedCrossRef

go back to reference Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.PubMedCrossRef Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.PubMedCrossRef

go back to reference Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in OS. Cancer Lett. 2017;386:189–95.PubMedCrossRef Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in OS. Cancer Lett. 2017;386:189–95.PubMedCrossRef

go back to reference Adhikari AS, Agarwal N, Wood BM. CD117 and Stro-1 identify OS tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 2010;70(11):4602–12.PubMedPubMedCentralCrossRef Adhikari AS, Agarwal N, Wood BM. CD117 and Stro-1 identify OS tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 2010;70(11):4602–12.PubMedPubMedCentralCrossRef

go back to reference He A, Qi W, Huang Y. CD133 expression predicts lung metastasis and poor prognosis in OS patients: a clinical and experimental study. Exp Ther Med. 2012;4(3):435–41.PubMedPubMedCentralCrossRef He A, Qi W, Huang Y. CD133 expression predicts lung metastasis and poor prognosis in OS patients: a clinical and experimental study. Exp Ther Med. 2012;4(3):435–41.PubMedPubMedCentralCrossRef

go back to reference Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 2011;25(6):2022–30.PubMedCrossRef Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 2011;25(6):2022–30.PubMedCrossRef

go back to reference Zhang D, Zhao Q, Sun H, Yin L, Wu J, Xu J. Defective autophagy leads to the suppression of stem-like features of CD271 (+) OS cells. J Biomed Sci. 2016;23(1):82.PubMedPubMedCentralCrossRef Zhang D, Zhao Q, Sun H, Yin L, Wu J, Xu J. Defective autophagy leads to the suppression of stem-like features of CD271 (+) OS cells. J Biomed Sci. 2016;23(1):82.PubMedPubMedCentralCrossRef

go back to reference Tian J, Li X, Si M, Liu T, Li J. CD271+ OS cells display stem-like properties. PLoS ONE. 2014;9(6):e98549.PubMedPubMedCentralCrossRef Tian J, Li X, Si M, Liu T, Li J. CD271+ OS cells display stem-like properties. PLoS ONE. 2014;9(6):e98549.PubMedPubMedCentralCrossRef

go back to reference Wang L, Park P, Zhang H, La Marca F, Lin CY. Prospective identification of tumorigenic OS cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer. 2011;128(2):294–303.PubMedCrossRef Wang L, Park P, Zhang H, La Marca F, Lin CY. Prospective identification of tumorigenic OS cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer. 2011;128(2):294–303.PubMedCrossRef

go back to reference Marcato P, Dean CA, Giacomantonio CA, Lee PWK. Aldehyde dehydrogenase its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle. 2011;10(9):1378–84.PubMedCrossRef Marcato P, Dean CA, Giacomantonio CA, Lee PWK. Aldehyde dehydrogenase its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle. 2011;10(9):1378–84.PubMedCrossRef

go back to reference Zhou F, Mu YD, Liang J. Aldehyde dehydrogenase 1: a specific cancer stem cell marker for human colorectal carcinoma. Mol Med Rep. 2015;11(5):3894–9.PubMedCrossRef Zhou F, Mu YD, Liang J. Aldehyde dehydrogenase 1: a specific cancer stem cell marker for human colorectal carcinoma. Mol Med Rep. 2015;11(5):3894–9.PubMedCrossRef

go back to reference Mu X, Patel S, Mektepbayeva D, Mahjoub A, Huard J, Weiss K. Retinal targets ALDH positive cancer stem cell and alters the phenotype of highly metastatic OS cells. Sarcoma. 2015;2015:784954.PubMedPubMedCentralCrossRef Mu X, Patel S, Mektepbayeva D, Mahjoub A, Huard J, Weiss K. Retinal targets ALDH positive cancer stem cell and alters the phenotype of highly metastatic OS cells. Sarcoma. 2015;2015:784954.PubMedPubMedCentralCrossRef

go back to reference Greco N, Schott T, Mu X, Rothenberg A, Voigt C, McGough RL 3rd, et al. ALDH activity correlates with metastatic potential in primary sarcomas of bone. J Cancer Ther. 2014;5(4):331–8.PubMedPubMedCentralCrossRef Greco N, Schott T, Mu X, Rothenberg A, Voigt C, McGough RL 3rd, et al. ALDH activity correlates with metastatic potential in primary sarcomas of bone. J Cancer Ther. 2014;5(4):331–8.PubMedPubMedCentralCrossRef

go back to reference Uluçkan Ö, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, Frazier WA, Weilbaecher KN. CD47 regulates bone mass and tumor metastasis to bone. Cancer Res. 2009;69(7):3196–204.PubMedPubMedCentralCrossRef Uluçkan Ö, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, Frazier WA, Weilbaecher KN. CD47 regulates bone mass and tumor metastasis to bone. Cancer Res. 2009;69(7):3196–204.PubMedPubMedCentralCrossRef

go back to reference Xu JF, Pan XH, Zhang SJ. CD47 blockade inhibits tumor progression human OS in xenograft models. Oncotarget. 2015;6(27):23662–70.PubMedPubMedCentral Xu JF, Pan XH, Zhang SJ. CD47 blockade inhibits tumor progression human OS in xenograft models. Oncotarget. 2015;6(27):23662–70.PubMedPubMedCentral

go back to reference Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8(5):411–24.PubMedCrossRef Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8(5):411–24.PubMedCrossRef

go back to reference Tirino V, Desiderio V, D’aquino R. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLos ONE. 2008;3:e3469.PubMedPubMedCentralCrossRef Tirino V, Desiderio V, D’aquino R. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLos ONE. 2008;3:e3469.PubMedPubMedCentralCrossRef

go back to reference Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010;86:631–7.PubMedCrossRef Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010;86:631–7.PubMedCrossRef

go back to reference Kim CK, Oh S, Kim SJ, Leem SH, Heo J, Chung SH. Correlation of IGF1R expression with ABCG2 and CD44 expressions in human osteosarcoma. Genes Genomics. 2018;40(4):381–8.PubMedCrossRef Kim CK, Oh S, Kim SJ, Leem SH, Heo J, Chung SH. Correlation of IGF1R expression with ABCG2 and CD44 expressions in human osteosarcoma. Genes Genomics. 2018;40(4):381–8.PubMedCrossRef

go back to reference Gatti L, Beretta GL, Cossa G, Zunino F, Perego P. ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem. 2009;9(9):1102–12.PubMedCrossRef Gatti L, Beretta GL, Cossa G, Zunino F, Perego P. ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem. 2009;9(9):1102–12.PubMedCrossRef

go back to reference Fanelli M, Hattinger CM, Vella S. Targeting ABCB1 and ABCC1 with their specific inhibitor CBT-1(R) can overcome drug resistance in OS. Curr Cancer Drug Targets. 2016;16(3):261–74.PubMedCrossRef Fanelli M, Hattinger CM, Vella S. Targeting ABCB1 and ABCC1 with their specific inhibitor CBT-1(R) can overcome drug resistance in OS. Curr Cancer Drug Targets. 2016;16(3):261–74.PubMedCrossRef

go back to reference Hattinger CM, Fanelli M, Tavanti E, Vella S, Riganti C, Picci P. Doxorubicin-resistant OS: novel therapeutic approaches in sight? Future Oncol. 2017;13(8):673–7.PubMedCrossRef Hattinger CM, Fanelli M, Tavanti E, Vella S, Riganti C, Picci P. Doxorubicin-resistant OS: novel therapeutic approaches in sight? Future Oncol. 2017;13(8):673–7.PubMedCrossRef

go back to reference Saini V, Hose CD, Monks A. Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in OS. PLoS ONE. 2012;7(8):e41401.PubMedPubMedCentralCrossRef Saini V, Hose CD, Monks A. Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in OS. PLoS ONE. 2012;7(8):e41401.PubMedPubMedCentralCrossRef

go back to reference Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, Kandel R. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res. 2007;67(17):8216–22.PubMedCrossRef Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, Kandel R. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res. 2007;67(17):8216–22.PubMedCrossRef

go back to reference Yang M, Zhang R, Yan M, Ye Z, Liang W, Luo Z. Detection and characterization of side population in Ewing’s sarcoma SK-ES-1 cells in vitro. Biochem Biophys Res Commun. 2010;391(1):1062–6.PubMedCrossRef Yang M, Zhang R, Yan M, Ye Z, Liang W, Luo Z. Detection and characterization of side population in Ewing’s sarcoma SK-ES-1 cells in vitro. Biochem Biophys Res Commun. 2010;391(1):1062–6.PubMedCrossRef

go back to reference Sun DX, Liao GJ, Liu KG, Jian H. Endosialin-expressing bone sarcoma stem-like cells are highly tumor-initiating and invasive. Mol Med Rep. 2015;12(4):5665–70.PubMedPubMedCentralCrossRef Sun DX, Liao GJ, Liu KG, Jian H. Endosialin-expressing bone sarcoma stem-like cells are highly tumor-initiating and invasive. Mol Med Rep. 2015;12(4):5665–70.PubMedPubMedCentralCrossRef

go back to reference Zambo I, Hermanova M, Adamkova KD. Nestin expression in high-grade OSs and its clinical significance. Oncol Rep. 2012;27:1592–8.PubMed Zambo I, Hermanova M, Adamkova KD. Nestin expression in high-grade OSs and its clinical significance. Oncol Rep. 2012;27:1592–8.PubMed

go back to reference Veselska R, Hermanova M, Loja T, Chlapek P, Zambo I, Vesely K. Nestin expression in OSs and derivation of nestin/CD133 positive OS cell lines. BMC Cancer. 2008;8:300.PubMedPubMedCentralCrossRef Veselska R, Hermanova M, Loja T, Chlapek P, Zambo I, Vesely K. Nestin expression in OSs and derivation of nestin/CD133 positive OS cell lines. BMC Cancer. 2008;8:300.PubMedPubMedCentralCrossRef

go back to reference Agliano A, Calvo A, Box C. The challenge of targeting cancer stem cells tohalt metastasis. Semin Cancer Biol. 2017;44:25–42.PubMedCrossRef Agliano A, Calvo A, Box C. The challenge of targeting cancer stem cells tohalt metastasis. Semin Cancer Biol. 2017;44:25–42.PubMedCrossRef

go back to reference Golbakhsh MR, Boddouhi B, Hatami N, Goudarzi PK, Shakeri M, Yahaghi E, Taheriazam A. Down-regulation of microRNA-182 and microRNA-183 predicts progression of OS. Arch Med Sci. 2017;13(6):1352–6.PubMedCrossRef Golbakhsh MR, Boddouhi B, Hatami N, Goudarzi PK, Shakeri M, Yahaghi E, Taheriazam A. Down-regulation of microRNA-182 and microRNA-183 predicts progression of OS. Arch Med Sci. 2017;13(6):1352–6.PubMedCrossRef

go back to reference Garg M. Emerging role of microRNAs in cancer stem cells: implications in cancer therapy World. J Stem Cells. 2015;7(8):1078–89.CrossRef Garg M. Emerging role of microRNAs in cancer stem cells: implications in cancer therapy World. J Stem Cells. 2015;7(8):1078–89.CrossRef

go back to reference Gobin B, Huin MB, Lamoureux F, Ory B, Charrier C, Lanel R, Battaglia S, Redini F, Lezot F, Blanchard F, Heymann D. BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of OS. Int J Cancer. 2015;136(4):784–96.PubMedCrossRef Gobin B, Huin MB, Lamoureux F, Ory B, Charrier C, Lanel R, Battaglia S, Redini F, Lezot F, Blanchard F, Heymann D. BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of OS. Int J Cancer. 2015;136(4):784–96.PubMedCrossRef

go back to reference Lu J, Song G, Tang Q, Yin J, Zou C, Zhao Z, Xie X, Xu H, Huang G, Wang J, Lee DF, Khokha R, Yang H, Shen J. MiR-26a inhibits stem cell-like phenotype and tumor growth of OS by targeting Jagged1. Oncogene. 2017;36(2):231–41.PubMedCrossRef Lu J, Song G, Tang Q, Yin J, Zou C, Zhao Z, Xie X, Xu H, Huang G, Wang J, Lee DF, Khokha R, Yang H, Shen J. MiR-26a inhibits stem cell-like phenotype and tumor growth of OS by targeting Jagged1. Oncogene. 2017;36(2):231–41.PubMedCrossRef

go back to reference Wang Y, Yao J, Meng H, Yu Z, Wang Z, Yuan X. A novel long non-coding RNA, hypoxia-inducible factor-2α promoter upstream transcript, functions as an inhibitor of OS stem cells in vitro. Mol Med Rep. 2015;11(4):2534–40.PubMedCrossRef Wang Y, Yao J, Meng H, Yu Z, Wang Z, Yuan X. A novel long non-coding RNA, hypoxia-inducible factor-2α promoter upstream transcript, functions as an inhibitor of OS stem cells in vitro. Mol Med Rep. 2015;11(4):2534–40.PubMedCrossRef

go back to reference Zhou X, Wang G, Sun Y. A reliable parameter to standardize the scoring of stem cell spheres. PLoS ONE. 2015;10(5):e0127348.PubMedPubMedCentralCrossRef Zhou X, Wang G, Sun Y. A reliable parameter to standardize the scoring of stem cell spheres. PLoS ONE. 2015;10(5):e0127348.PubMedPubMedCentralCrossRef

go back to reference Wang L, Park P, Lin CY. Characterization of stem cell attributes in human OS cell lines. Cancer Biol Ther. 2009;8(6):543–52.PubMedCrossRef Wang L, Park P, Lin CY. Characterization of stem cell attributes in human OS cell lines. Cancer Biol Ther. 2009;8(6):543–52.PubMedCrossRef

go back to reference Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Takakura Y. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol. 2009;34(5):1381–6.PubMed Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Takakura Y. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol. 2009;34(5):1381–6.PubMed

go back to reference Martins-Neves SR, Lopes ÁO, do Carmo A. Therapeutic implications of an enriched cancer stem-like cell population in a human OS cell line. BMC Cancer. 2012;12:139.PubMedPubMedCentralCrossRef Martins-Neves SR, Lopes ÁO, do Carmo A. Therapeutic implications of an enriched cancer stem-like cell population in a human OS cell line. BMC Cancer. 2012;12:139.PubMedPubMedCentralCrossRef

go back to reference Palmini G, Zonefrati R, Romagnoli C, Aldinucci A, Mavilia C, Leoncini G. Establishment and characterization of a human small cell os cancer stem cell line: a new possible in vitro model for discovering small cell OS biology. Stem Cells Int. 2016;2016:3042198.PubMedPubMedCentralCrossRef Palmini G, Zonefrati R, Romagnoli C, Aldinucci A, Mavilia C, Leoncini G. Establishment and characterization of a human small cell os cancer stem cell line: a new possible in vitro model for discovering small cell OS biology. Stem Cells Int. 2016;2016:3042198.PubMedPubMedCentralCrossRef

go back to reference Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang P. Transforming growth factor β1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in OS. Stem Cells. 2013;31(3):433–46.PubMedCrossRef Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang P. Transforming growth factor β1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in OS. Stem Cells. 2013;31(3):433–46.PubMedCrossRef

go back to reference Chen X, Hu C, Zhang W, Shen Y, Wang J, Hu F. Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in OS MG63 cells in vitro. Tumour Biol. 2015;36(12):9873–83.PubMedCrossRef Chen X, Hu C, Zhang W, Shen Y, Wang J, Hu F. Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in OS MG63 cells in vitro. Tumour Biol. 2015;36(12):9873–83.PubMedCrossRef

go back to reference Bapat SA. Epigenetic regulation of cancer stem cell gene expression. Subcell Biochem. 2013;61:419–34.PubMedCrossRef Bapat SA. Epigenetic regulation of cancer stem cell gene expression. Subcell Biochem. 2013;61:419–34.PubMedCrossRef

go back to reference Yan GN, Tang XF, Zhang XC, He T, Huang YS, Zhang X, Meng G, Guo DY, Lv YF, Guo QN. TSSC3 represses self-renewal of OS stem cells and Nanog expression by inhibiting the Src/Akt pathway. Oncotarget. 2017;8(49):85628–41.PubMedPubMedCentral Yan GN, Tang XF, Zhang XC, He T, Huang YS, Zhang X, Meng G, Guo DY, Lv YF, Guo QN. TSSC3 represses self-renewal of OS stem cells and Nanog expression by inhibiting the Src/Akt pathway. Oncotarget. 2017;8(49):85628–41.PubMedPubMedCentral

go back to reference Gemei M, Corbo C, D’Alessio F, Di Noto R, Vento R, Del Vecchio L. Surface proteomic analysis of differentiated versus stem-like OS human cells. Proteomics. 2013;13(22):3293–7.PubMedCrossRef Gemei M, Corbo C, D’Alessio F, Di Noto R, Vento R, Del Vecchio L. Surface proteomic analysis of differentiated versus stem-like OS human cells. Proteomics. 2013;13(22):3293–7.PubMedCrossRef

go back to reference Di Fiore R, Santulli A, Ferrante RD, Giuliano M, De Blasio A, Messina C, Pirozzi G, Tirino V, Tesoriere G, Vento R. Identification and expansion of human OScancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol. 2009;219:301–13.PubMedCrossRef Di Fiore R, Santulli A, Ferrante RD, Giuliano M, De Blasio A, Messina C, Pirozzi G, Tirino V, Tesoriere G, Vento R. Identification and expansion of human OScancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol. 2009;219:301–13.PubMedCrossRef

go back to reference Chandhanayingyong C, Kim Y, Staples JR, Hahn C, Lee FY. MAPK/ERK signaling in OSs, Ewing sarcomas and chondrosarcomas: therapeutic implications and future directions. Sarcoma. 2012;2012:404810.PubMedPubMedCentralCrossRef Chandhanayingyong C, Kim Y, Staples JR, Hahn C, Lee FY. MAPK/ERK signaling in OSs, Ewing sarcomas and chondrosarcomas: therapeutic implications and future directions. Sarcoma. 2012;2012:404810.PubMedPubMedCentralCrossRef

go back to reference Wu F, Zhang Y, Sun B, McMahon AP, Wang Y. Hedgehog signaling: from basic biology to cancer therapy. Cell Chem Biol. 2017;24(3):252–80.PubMedCrossRefPubMedCentral Wu F, Zhang Y, Sun B, McMahon AP, Wang Y. Hedgehog signaling: from basic biology to cancer therapy. Cell Chem Biol. 2017;24(3):252–80.PubMedCrossRefPubMedCentral

go back to reference Miyaji T, Nakase T, Iwasaki M, Kuriyama K, Tamai N. Expression and distribution of transcripts for sonic hedgehog in the early phase of fracture repair. Histochem Cell Biol. 2003;119:233–7.PubMed Miyaji T, Nakase T, Iwasaki M, Kuriyama K, Tamai N. Expression and distribution of transcripts for sonic hedgehog in the early phase of fracture repair. Histochem Cell Biol. 2003;119:233–7.PubMed

go back to reference Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004;431(7009):707–12.PubMedCrossRef Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004;431(7009):707–12.PubMedCrossRef

go back to reference Ochoa B, Syn WK, Delgado I, Karaca GF, Jung Y, Wang J, Zubiaga AM, Fresnedo O, Omenetti A. Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology. 2010;51(5):1712–23.PubMedCrossRef Ochoa B, Syn WK, Delgado I, Karaca GF, Jung Y, Wang J, Zubiaga AM, Fresnedo O, Omenetti A. Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology. 2010;51(5):1712–23.PubMedCrossRef

go back to reference Shin K, Lee J, Guo N, Kim J, Lim A, Qu L, Mysorekar IU, Beachy PA. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature. 2011;472(7341):110–4.PubMedPubMedCentralCrossRef Shin K, Lee J, Guo N, Kim J, Lim A, Qu L, Mysorekar IU, Beachy PA. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature. 2011;472(7341):110–4.PubMedPubMedCentralCrossRef

go back to reference Justilien V, Fields AP. Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. Clin Cancer Res. 2015;21(3):505–13.PubMedPubMedCentralCrossRef Justilien V, Fields AP. Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. Clin Cancer Res. 2015;21(3):505–13.PubMedPubMedCentralCrossRef

go back to reference Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ, Yoon SS. CD44 expression denotes a subpopulation of gastric cancer cells in which hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res. 2014;20:3974–88.PubMedPubMedCentralCrossRef Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ, Yoon SS. CD44 expression denotes a subpopulation of gastric cancer cells in which hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res. 2014;20:3974–88.PubMedPubMedCentralCrossRef

go back to reference Lo WW, Pinnaduwage D, Gokgoz N, Wunder JS, Andrulis IL. Aberrant hedgehog signaling and clinical outcome in OS. Sarcoma. 2014;2014:261804.PubMedPubMedCentralCrossRef Lo WW, Pinnaduwage D, Gokgoz N, Wunder JS, Andrulis IL. Aberrant hedgehog signaling and clinical outcome in OS. Sarcoma. 2014;2014:261804.PubMedPubMedCentralCrossRef

go back to reference Ram Kumar RM, Fuchs B. Hedgehog signaling inhibitors as anti-cancer agents in OS. Cancers. 2015;7(2):784–94.PubMedPubMedCentralCrossRef Ram Kumar RM, Fuchs B. Hedgehog signaling inhibitors as anti-cancer agents in OS. Cancers. 2015;7(2):784–94.PubMedPubMedCentralCrossRef

go back to reference Sharma N, Nanta R, Sharma J, Gunewardena S, Singh KP, Shankar S. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. Oncotarget. 2015;6(31):32039–60.PubMedPubMedCentralCrossRef Sharma N, Nanta R, Sharma J, Gunewardena S, Singh KP, Shankar S. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. Oncotarget. 2015;6(31):32039–60.PubMedPubMedCentralCrossRef

go back to reference Dlugosz A, Agrawal S, Kirkpatrick P. Vismodegib. Nat Rev Drug Discov. 2012;11(6):437–8.PubMedCrossRef Dlugosz A, Agrawal S, Kirkpatrick P. Vismodegib. Nat Rev Drug Discov. 2012;11(6):437–8.PubMedCrossRef

go back to reference Burness CB. Sonidegib: first global approval. Drugs. 2015;75(13):1559–66.PubMedCrossRef Burness CB. Sonidegib: first global approval. Drugs. 2015;75(13):1559–66.PubMedCrossRef

go back to reference Kelleher FC, Cain JE, Healy JM, Watkins DN, Thomas DM. Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther. 2012;136:153–68.PubMedCrossRef Kelleher FC, Cain JE, Healy JM, Watkins DN, Thomas DM. Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther. 2012;136:153–68.PubMedCrossRef

go back to reference Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2018;62:50–60.PubMedCrossRef Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2018;62:50–60.PubMedCrossRef

go back to reference Alfranca A, Martinez-Cruzado L, Tornin J, Abarrategi A, Amaral T, de Alava E. Bone microenvironment signals in OS development. Cell Mol Life Sci. 2015;72(16):3097–113.PubMedCrossRef Alfranca A, Martinez-Cruzado L, Tornin J, Abarrategi A, Amaral T, de Alava E. Bone microenvironment signals in OS development. Cell Mol Life Sci. 2015;72(16):3097–113.PubMedCrossRef

go back to reference Lin CH, Ji T, Chen CF, Hoang BH. Wnt signaling in OS. Adv Exp Med Biol. 2014;804:33–45.PubMedCrossRef Lin CH, Ji T, Chen CF, Hoang BH. Wnt signaling in OS. Adv Exp Med Biol. 2014;804:33–45.PubMedCrossRef

go back to reference Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs JJ, Gitelis S, O’Keefe RJ, Konttinen YT, Yin G, Li TF. Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes OS cells to chemotherapy. Biochem Biophys Res Commun. 2013;431(2):274–9.PubMedPubMedCentralCrossRef Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs JJ, Gitelis S, O’Keefe RJ, Konttinen YT, Yin G, Li TF. Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes OS cells to chemotherapy. Biochem Biophys Res Commun. 2013;431(2):274–9.PubMedPubMedCentralCrossRef

go back to reference Yi XJ, Zhao YH, Qiao LX, Jin CL, Tian J, Li QS. Aberrant Wnt/β-catenin signaling and elevated expression of stem cell proteins are associated with OS side population cells of high tumorigenicity. Mol Med Rep. 2015;12(4):5042–8.PubMedPubMedCentralCrossRef Yi XJ, Zhao YH, Qiao LX, Jin CL, Tian J, Li QS. Aberrant Wnt/β-catenin signaling and elevated expression of stem cell proteins are associated with OS side population cells of high tumorigenicity. Mol Med Rep. 2015;12(4):5042–8.PubMedPubMedCentralCrossRef

go back to reference Tang QL, Zhao ZQ, Li JC, Liang Y, Yin JQ, Zou CY, Xie XB, Zeng YX, Shen JN, Kang T, Wang J. Salinomycin inhibits OS by targeting its tumor stem cells. Cancer Lett. 2011;311(1):113–21.PubMedCrossRef Tang QL, Zhao ZQ, Li JC, Liang Y, Yin JQ, Zou CY, Xie XB, Zeng YX, Shen JN, Kang T, Wang J. Salinomycin inhibits OS by targeting its tumor stem cells. Cancer Lett. 2011;311(1):113–21.PubMedCrossRef

go back to reference Stratford EW, Daffinrud J, Munthe E, Castro R, Waaler J, Krauss S, Myklebost O. The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in OS cell lines. Cancer Med. 2014;3(1):36–46.PubMedCrossRef Stratford EW, Daffinrud J, Munthe E, Castro R, Waaler J, Krauss S, Myklebost O. The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in OS cell lines. Cancer Med. 2014;3(1):36–46.PubMedCrossRef

go back to reference Zhong Y, Katavolos P, Nguyen T, Lau T, Boggs J, Sambrone A, Kan D. Tankyrase inhibition causes reversible intestinal toxicity in mice with a therapeutic index < 1. Toxicol Pathol. 2016;44(2):267–78.PubMedCrossRef Zhong Y, Katavolos P, Nguyen T, Lau T, Boggs J, Sambrone A, Kan D. Tankyrase inhibition causes reversible intestinal toxicity in mice with a therapeutic index < 1. Toxicol Pathol. 2016;44(2):267–78.PubMedCrossRef

go back to reference Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/beta-catenin pathway in conventional high-grade OS. J Pathol. 2010;220(1):24–33.PubMedCrossRef Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/beta-catenin pathway in conventional high-grade OS. J Pathol. 2010;220(1):24–33.PubMedCrossRef

go back to reference Du X, Yang J, Yang D, Tian W, Zhu Z. The genetic basis for inactivation of Wnt pathway in human OS. BMC Cancer. 2014;14:450.PubMedPubMedCentralCrossRef Du X, Yang J, Yang D, Tian W, Zhu Z. The genetic basis for inactivation of Wnt pathway in human OS. BMC Cancer. 2014;14:450.PubMedPubMedCentralCrossRef

go back to reference Weekes C, Berlin J, Lenz HJ, O’Neil B, Messersmith W, Cohen S. Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC). Ann Oncol. 2016;27(suppl 6):367PD. Weekes C, Berlin J, Lenz HJ, O’Neil B, Messersmith W, Cohen S. Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC). Ann Oncol. 2016;27(suppl 6):367PD.

go back to reference Staal FJ, Sen JM. The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis. Eur J Immunol. 2008;38:1788–94.PubMedPubMedCentralCrossRef Staal FJ, Sen JM. The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis. Eur J Immunol. 2008;38:1788–94.PubMedPubMedCentralCrossRef

go back to reference Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013;34:1420–30.PubMedPubMedCentralCrossRef Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013;34:1420–30.PubMedPubMedCentralCrossRef

go back to reference Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, Wu GS, Wu K. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369(1):20–7.PubMedCrossRef Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, Wu GS, Wu K. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369(1):20–7.PubMedCrossRef

go back to reference Venkatesh V, Nataraj R, Thangaraj GS, Karthikeyan M, Gnanasekaran A, Kaginelli SB, Kuppanna G, Kallappa CG, Basalingappa KM. Targeting Notch signalling pathway of cancer stem cells. Stem Cell Investig. 2018;5:5.PubMedPubMedCentralCrossRef Venkatesh V, Nataraj R, Thangaraj GS, Karthikeyan M, Gnanasekaran A, Kaginelli SB, Kuppanna G, Kallappa CG, Basalingappa KM. Targeting Notch signalling pathway of cancer stem cells. Stem Cell Investig. 2018;5:5.PubMedPubMedCentralCrossRef

go back to reference McManus MM, Weiss KR, Hughes DP. Understanding the role of Notch in OS. Adv Exp Med Biol. 2014;804:67–92.PubMedCrossRef McManus MM, Weiss KR, Hughes DP. Understanding the role of Notch in OS. Adv Exp Med Biol. 2014;804:67–92.PubMedCrossRef

go back to reference Hughes DP. How the NOTCH pathway contributes to the ability of OS cells to metastasize. Cancer Treat Res. 2009;152:479–96.PubMedCrossRef Hughes DP. How the NOTCH pathway contributes to the ability of OS cells to metastasize. Cancer Treat Res. 2009;152:479–96.PubMedCrossRef

go back to reference Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014;141:140–9.PubMedCrossRef Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014;141:140–9.PubMedCrossRef

go back to reference So JY, Wahler J, Das Gupta S, Salerno DM, Maehr H, Uskokovic M, Suh N. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer. J Steroid Biochem Mol Biol. 2015;148:111–21.PubMedCrossRef So JY, Wahler J, Das Gupta S, Salerno DM, Maehr H, Uskokovic M, Suh N. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer. J Steroid Biochem Mol Biol. 2015;148:111–21.PubMedCrossRef

go back to reference Tao J, Jiang MM, Jiang L. Notch activation as a driver of osteogenic sarcoma. Cancer Cell. 2014;26(3):390–401.PubMedPubMedCentralCrossRef Tao J, Jiang MM, Jiang L. Notch activation as a driver of osteogenic sarcoma. Cancer Cell. 2014;26(3):390–401.PubMedPubMedCentralCrossRef

go back to reference McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X, Hoang BH. The Wnt signaling pathway: implications for therapy in OS. Expert Rev Anticancer Ther. 2011;11(8):1223–32.PubMedCrossRef McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X, Hoang BH. The Wnt signaling pathway: implications for therapy in OS. Expert Rev Anticancer Ther. 2011;11(8):1223–32.PubMedCrossRef

go back to reference Jiang LY, Zhang XL, Du P, Zheng JH. γ-Secretase inhibitor, DAPT inhibits self-renewal and stemness maintenance of ovarian cancer stem-like cells in vitro. Chin J Cancer Res. 2011;23(2):140–6.PubMedPubMedCentralCrossRef Jiang LY, Zhang XL, Du P, Zheng JH. γ-Secretase inhibitor, DAPT inhibits self-renewal and stemness maintenance of ovarian cancer stem-like cells in vitro. Chin J Cancer Res. 2011;23(2):140–6.PubMedPubMedCentralCrossRef

go back to reference Mizugaki H, Sakakibara-Konishi J, Ikezawa Y, Kikuchi J, Kikuchi E, Oizumi S. γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer. Br J Cancer. 2012;106(12):1953–9.PubMedPubMedCentralCrossRef Mizugaki H, Sakakibara-Konishi J, Ikezawa Y, Kikuchi J, Kikuchi E, Oizumi S. γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer. Br J Cancer. 2012;106(12):1953–9.PubMedPubMedCentralCrossRef

go back to reference Mittal S, Sharma A, Balaji SA, Gowda MC, Dighe RR, Kumar RV. Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers. Mol Cancer Ther. 2014;13(12):3198–209.PubMedPubMedCentralCrossRef Mittal S, Sharma A, Balaji SA, Gowda MC, Dighe RR, Kumar RV. Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers. Mol Cancer Ther. 2014;13(12):3198–209.PubMedPubMedCentralCrossRef

go back to reference McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA. 2012;109(43):E2939–48.PubMedCrossRefPubMedCentral McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA. 2012;109(43):E2939–48.PubMedCrossRefPubMedCentral

go back to reference Mu X, Isaac C, Greco N, Huard J, Weiss K. Notch signaling is associated with ALDH activity and an aggressive metastatic phenotype in murine OS cells. Front Oncol. 2013;3:143.PubMedPubMedCentralCrossRef Mu X, Isaac C, Greco N, Huard J, Weiss K. Notch signaling is associated with ALDH activity and an aggressive metastatic phenotype in murine OS cells. Front Oncol. 2013;3:143.PubMedPubMedCentralCrossRef

go back to reference Yap TA, Bjerke L, Clarke PA, Workman P. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol. 2015;23:98–107.PubMedPubMedCentralCrossRef Yap TA, Bjerke L, Clarke PA, Workman P. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol. 2015;23:98–107.PubMedPubMedCentralCrossRef

go back to reference Gong C, Liao H, Wang J, Lin Y, Qi J, Qin L, Tian LQ, Guo FJ. LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human OS via downregulation of PI3K activity. Asian Pac J Cancer Prev. 2012;13(7):3103–7.PubMedCrossRef Gong C, Liao H, Wang J, Lin Y, Qi J, Qin L, Tian LQ, Guo FJ. LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human OS via downregulation of PI3K activity. Asian Pac J Cancer Prev. 2012;13(7):3103–7.PubMedCrossRef

go back to reference Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, Ricono J. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. Cancer Res. 2015;75(2):446–55.PubMedCrossRef Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, Ricono J. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. Cancer Res. 2015;75(2):446–55.PubMedCrossRef

go back to reference Zuch D, Giang AH, Shapovalov Y, Schwarz E, Rosier R, O’Keefe R, Eliseev RA. Targeting radioresistant osteosarcoma cells with parthenolide. J Cell Biochem. 2012;113:1282–91.PubMedPubMedCentralCrossRef Zuch D, Giang AH, Shapovalov Y, Schwarz E, Rosier R, O’Keefe R, Eliseev RA. Targeting radioresistant osteosarcoma cells with parthenolide. J Cell Biochem. 2012;113:1282–91.PubMedPubMedCentralCrossRef

go back to reference Mongre RK, Sodhi SS, Ghosh M, Kim JH, Kim N, Park YH, Kim SJ, Heo YJ, Sharma N, Jeong DK. The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells. Int J Oncol. 2015;46(6):2573–85.PubMedCrossRef Mongre RK, Sodhi SS, Ghosh M, Kim JH, Kim N, Park YH, Kim SJ, Heo YJ, Sharma N, Jeong DK. The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells. Int J Oncol. 2015;46(6):2573–85.PubMedCrossRef

go back to reference Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol. 2008;48:171–97.PubMedCrossRef Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol. 2008;48:171–97.PubMedCrossRef

go back to reference Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31–82.PubMedPubMedCentralCrossRef Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31–82.PubMedPubMedCentralCrossRef

go back to reference Roato I, Ferracini R. Cancer stem cells, bone and tumor microenvironment: key players in bone metastases. Cancers. 2018;10(2):E56. https://doi.org/10.3390/cancers10020056.CrossRefPubMed Roato I, Ferracini R. Cancer stem cells, bone and tumor microenvironment: key players in bone metastases. Cancers. 2018;10(2):E56. https://​doi.​org/​10.​3390/​cancers10020056.CrossRefPubMed

go back to reference Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, Liles WC, Li X, Graham-Evans B, Campbell TB, Calandra G, Bridger G, Dale DC, Srour EF. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with amd3100, a cxcr4 antagonist. J Exp Med. 2005;201:1307–18.PubMedPubMedCentralCrossRef Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, Liles WC, Li X, Graham-Evans B, Campbell TB, Calandra G, Bridger G, Dale DC, Srour EF. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with amd3100, a cxcr4 antagonist. J Exp Med. 2005;201:1307–18.PubMedPubMedCentralCrossRef

go back to reference Siclari VA, Qin L. Targeting the OS cancer stem cell. J Orthop Surg Res. 2010;5:78.PubMedPubMedCentralCrossRef Siclari VA, Qin L. Targeting the OS cancer stem cell. J Orthop Surg Res. 2010;5:78.PubMedPubMedCentralCrossRef

go back to reference Burwick N, Moreau AS, Jia X, Leleu X, Runnels J, Ngo HT, Melhem MR, Roccaro AM, Azab AK, Ghobrial IM. CXCR7 regulates SDF-1 induced adhesion and homing in multiple myeloma. Blood. 2008;112(11):1674. Burwick N, Moreau AS, Jia X, Leleu X, Runnels J, Ngo HT, Melhem MR, Roccaro AM, Azab AK, Ghobrial IM. CXCR7 regulates SDF-1 induced adhesion and homing in multiple myeloma. Blood. 2008;112(11):1674.

go back to reference Xu H, Wu Q, Dang S, Jin M, Xu J, Cheng Y, Pan M, Wu Y, Zhang C, Zhang Y. Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS ONE. 2011;6(12):e27399.PubMedPubMedCentralCrossRef Xu H, Wu Q, Dang S, Jin M, Xu J, Cheng Y, Pan M, Wu Y, Zhang C, Zhang Y. Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS ONE. 2011;6(12):e27399.PubMedPubMedCentralCrossRef

go back to reference Tarnowski M, Liu R, Wysoczynski M, Ratajczak J, Kucia M, Ratajczak MZ. CXCR7: a new SDF-1-binding receptor in contrast to normal CD34(+) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells. Eur J Haematol. 2010;85:472–83.PubMedCrossRef Tarnowski M, Liu R, Wysoczynski M, Ratajczak J, Kucia M, Ratajczak MZ. CXCR7: a new SDF-1-binding receptor in contrast to normal CD34(+) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells. Eur J Haematol. 2010;85:472–83.PubMedCrossRef

go back to reference Stephens PJ, Greenman CD, Fu B. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27–40.PubMedPubMedCentralCrossRef Stephens PJ, Greenman CD, Fu B. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27–40.PubMedPubMedCentralCrossRef

go back to reference Zeng W, Wan R, Zheng Y, Singh SR, Wei Y. Hypoxia, stem cells and bone tumor. Cancer Lett. 2011;313(2):129–36.PubMedPubMedCentralCrossRef Zeng W, Wan R, Zheng Y, Singh SR, Wei Y. Hypoxia, stem cells and bone tumor. Cancer Lett. 2011;313(2):129–36.PubMedPubMedCentralCrossRef

go back to reference Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer. 2010;102:789–95.PubMedPubMedCentralCrossRef Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer. 2010;102:789–95.PubMedPubMedCentralCrossRef

go back to reference Carnero A, Lleonart M. The hypoxic microenvironment: a determinant of cancerstem cell evolution. BioEssays. 2016;38:S65–74.PubMedCrossRef Carnero A, Lleonart M. The hypoxic microenvironment: a determinant of cancerstem cell evolution. BioEssays. 2016;38:S65–74.PubMedCrossRef

go back to reference Mazumdar J, Dondeti V, Simon MC. Hypoxia-inducible factors in stem cells and cancer. J Cell Mol Med. 2009;13:4319–28.PubMedPubMedCentralCrossRef Mazumdar J, Dondeti V, Simon MC. Hypoxia-inducible factors in stem cells and cancer. J Cell Mol Med. 2009;13:4319–28.PubMedPubMedCentralCrossRef

go back to reference Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell. 2009;5:237–41.PubMedCrossRef Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell. 2009;5:237–41.PubMedCrossRef

go back to reference Lau EY, Ho NP, Lee TK. Cancer stem cells and their microenvironment: biology and therapeutic Implications. Stem Cells Int. 2017;2017:3714190.PubMedPubMedCentralCrossRef Lau EY, Ho NP, Lee TK. Cancer stem cells and their microenvironment: biology and therapeutic Implications. Stem Cells Int. 2017;2017:3714190.PubMedPubMedCentralCrossRef

go back to reference Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest. 2007;117:862–5.PubMedPubMedCentralCrossRef Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest. 2007;117:862–5.PubMedPubMedCentralCrossRef

go back to reference Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med. 2001;7(8):345–50.PubMedCrossRef Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med. 2001;7(8):345–50.PubMedCrossRef

go back to reference Kim HS, Roh CR, Chen B, Tycko B, Nelson DM, Sadovsky Y. Hypoxia regulates the expression of PHLDA2 in primary term human trophoblasts. Placenta. 2007;28(2–3):77–84.PubMedCrossRef Kim HS, Roh CR, Chen B, Tycko B, Nelson DM, Sadovsky Y. Hypoxia regulates the expression of PHLDA2 in primary term human trophoblasts. Placenta. 2007;28(2–3):77–84.PubMedCrossRef

go back to reference Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA. 2007;104(13):5431–6.PubMedCrossRefPubMedCentral Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA. 2007;104(13):5431–6.PubMedCrossRefPubMedCentral

go back to reference Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335–48.PubMedCrossRef Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335–48.PubMedCrossRef

go back to reference Scatena R, Bottoni P, Giardina B. Circulating tumour cells and cancer stem cells: a role for proteomics in defining the interrelationships between function, phenotype and differentiation with potential clinical applications. Biochim Biophys Acta. 2013;1835(2):129–43.PubMed Scatena R, Bottoni P, Giardina B. Circulating tumour cells and cancer stem cells: a role for proteomics in defining the interrelationships between function, phenotype and differentiation with potential clinical applications. Biochim Biophys Acta. 2013;1835(2):129–43.PubMed

go back to reference Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010;288:99–106.PubMedCrossRef Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010;288:99–106.PubMedCrossRef

go back to reference Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–73.PubMedCrossRef Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–73.PubMedCrossRef

go back to reference Scatena R, Bottoni P, Pontoglio A, Giardina B. Cancer stem cells: the development of new cancer therapeutics. Expert Opin Biol Ther. 2011;11:875–92.PubMedCrossRef Scatena R, Bottoni P, Pontoglio A, Giardina B. Cancer stem cells: the development of new cancer therapeutics. Expert Opin Biol Ther. 2011;11:875–92.PubMedCrossRef

go back to reference Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR. Molecular biomarker analyses using circulating tumor cells. PLoS ONE. 2010;5(9):e12517.PubMedPubMedCentralCrossRef Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR. Molecular biomarker analyses using circulating tumor cells. PLoS ONE. 2010;5(9):e12517.PubMedPubMedCentralCrossRef

go back to reference Peach G, Kim C, Zacharakis E, Purkayastha S, Ziprin P. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer. 2010;102(9):1327–34.PubMedPubMedCentralCrossRef Peach G, Kim C, Zacharakis E, Purkayastha S, Ziprin P. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer. 2010;102(9):1327–34.PubMedPubMedCentralCrossRef

go back to reference Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008;123(9):1991–2006.PubMedCrossRef Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008;123(9):1991–2006.PubMedCrossRef

go back to reference Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem. 2011;57(9):1242–55.PubMedCrossRef Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem. 2011;57(9):1242–55.PubMedCrossRef

go back to reference Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59:110–8.PubMedCrossRef Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59:110–8.PubMedCrossRef

go back to reference Yang MH, Imrali A, Heeschen C. Circulating cancer stem cells: the importance to select. Chin J Cancer Res. 2015;27(5):437–49.PubMedPubMedCentral Yang MH, Imrali A, Heeschen C. Circulating cancer stem cells: the importance to select. Chin J Cancer Res. 2015;27(5):437–49.PubMedPubMedCentral

go back to reference Luo YT, Cheng J, Feng X, He SJ, Wang YW, Huang Q. The viable circulating tumor cells with cancer stem cells feature, where is the way out? J Exp Clin Cancer Res. 2018;37(1):38.PubMedPubMedCentralCrossRef Luo YT, Cheng J, Feng X, He SJ, Wang YW, Huang Q. The viable circulating tumor cells with cancer stem cells feature, where is the way out? J Exp Clin Cancer Res. 2018;37(1):38.PubMedPubMedCentralCrossRef

go back to reference Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol. 2010;2(6):351–65.PubMedPubMedCentralCrossRef Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol. 2010;2(6):351–65.PubMedPubMedCentralCrossRef

go back to reference Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, Liu J, Xu H, Wang Z. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. BMC Cancer. 2014;14:976.PubMedPubMedCentralCrossRef Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, Liu J, Xu H, Wang Z. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. BMC Cancer. 2014;14:976.PubMedPubMedCentralCrossRef

go back to reference Chalopin A, Tellez-Gabriel M, Brown HK, Vallette F, Heymann MF, Gouin F, Heymann D. Isolation of circulating tumor cells in a preclinical model of OS: effect of chemotherapy. J Bone Oncol. 2018;12:83–90.PubMedPubMedCentralCrossRef Chalopin A, Tellez-Gabriel M, Brown HK, Vallette F, Heymann MF, Gouin F, Heymann D. Isolation of circulating tumor cells in a preclinical model of OS: effect of chemotherapy. J Bone Oncol. 2018;12:83–90.PubMedPubMedCentralCrossRef

go back to reference Tellez-Gabriel M, Brown HK, Young R, Heymann MF, Heymann D. The challenges of detecting circulating tumor cells in sarcoma. Front Oncol. 2016;6:202.PubMedPubMedCentralCrossRef Tellez-Gabriel M, Brown HK, Young R, Heymann MF, Heymann D. The challenges of detecting circulating tumor cells in sarcoma. Front Oncol. 2016;6:202.PubMedPubMedCentralCrossRef

go back to reference Ségaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D. Interleukin-34 promotes tumor progression and metastatic process in OS through induction of angiogenesis and macrophage recruitment. Int J Cancer. 2015;137(1):73–85.PubMedCrossRef Ségaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D. Interleukin-34 promotes tumor progression and metastatic process in OS through induction of angiogenesis and macrophage recruitment. Int J Cancer. 2015;137(1):73–85.PubMedCrossRef

go back to reference Gabriel MT, Calleja LR, Chalopin A, Ory B, Heymann D. Circulating tumor cells: a review of non-EpCAM-based approaches for cell enrichment and isolation. Clin Chem. 2016;62(4):571–81.PubMedCrossRef Gabriel MT, Calleja LR, Chalopin A, Ory B, Heymann D. Circulating tumor cells: a review of non-EpCAM-based approaches for cell enrichment and isolation. Clin Chem. 2016;62(4):571–81.PubMedCrossRef

go back to reference Rodriguez Calleja L, Jacques C, Lamoureux F, Baud’huin M, Tellez Gabriel M, Quillard T, Sahay D, Perrot P, Amiaud J, Charrier C, Brion R, Lecanda F, Verrecchia F, Heymann D, Ellisen LW, Ory B. ΔNp63α silences a miRNA program to aberrantly initiate a wound-healing program that promotes TGFβ-induced metastasis. Cancer Res. 2016;76(11):3236–51.PubMedCrossRef Rodriguez Calleja L, Jacques C, Lamoureux F, Baud’huin M, Tellez Gabriel M, Quillard T, Sahay D, Perrot P, Amiaud J, Charrier C, Brion R, Lecanda F, Verrecchia F, Heymann D, Ellisen LW, Ory B. ΔNp63α silences a miRNA program to aberrantly initiate a wound-healing program that promotes TGFβ-induced metastasis. Cancer Res. 2016;76(11):3236–51.PubMedCrossRef

go back to reference Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014;74(6):1645–50.PubMedPubMedCentralCrossRef Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014;74(6):1645–50.PubMedPubMedCentralCrossRef

go back to reference Zhang H, Gao P, Xiao X, Heger M, Geng L, Fan B, Yuan Y, Huang C, Chen G, Liu Y, Hu Y, Yu X, Wu S, Wang L, Wang Z. A liquid biopsy-based method for the detection and quantification of circulating tumor cells in surgical steosarcoma patients. Int J Oncol. 2017;50(4):1075–86.PubMedCentralCrossRefPubMed Zhang H, Gao P, Xiao X, Heger M, Geng L, Fan B, Yuan Y, Huang C, Chen G, Liu Y, Hu Y, Yu X, Wu S, Wang L, Wang Z. A liquid biopsy-based method for the detection and quantification of circulating tumor cells in surgical steosarcoma patients. Int J Oncol. 2017;50(4):1075–86.PubMedCentralCrossRefPubMed

go back to reference Zhang HQ, Li MH, Wang Z, Lan PH, Lu YJ, Chen GJ, Wang L. Detection and clinical significance of circulating tumor cells in OS using immunofluorescence combined with in situ hybridization. Zhonghua Zhong Liu Za Zhi. 2017;39(7):485–9.PubMed Zhang HQ, Li MH, Wang Z, Lan PH, Lu YJ, Chen GJ, Wang L. Detection and clinical significance of circulating tumor cells in OS using immunofluorescence combined with in situ hybridization. Zhonghua Zhong Liu Za Zhi. 2017;39(7):485–9.PubMed

go back to reference Lianidou ES, Mavroudis D, Sotiropoulou G, Agelaki S, Pantel K. What’s new on circulating tumor cells? A meeting report. Breast Cancer Res. 2010;12(4):307.PubMedPubMedCentralCrossRef Lianidou ES, Mavroudis D, Sotiropoulou G, Agelaki S, Pantel K. What’s new on circulating tumor cells? A meeting report. Breast Cancer Res. 2010;12(4):307.PubMedPubMedCentralCrossRef

go back to reference Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012;2:995–1003.PubMedPubMedCentralCrossRef Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012;2:995–1003.PubMedPubMedCentralCrossRef

go back to reference Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4(6):650–61.PubMedPubMedCentralCrossRef Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4(6):650–61.PubMedPubMedCentralCrossRef

go back to reference Leung F, Kulasingam V, Diamandis EP, Hoon DS, Kinzler K, Pantel K, Alix-Panabières C. Circulating tumor DNA as a cancer biomarker: fact or fiction? Clin Chem. 2016;62(8):1054–60.PubMedPubMedCentralCrossRef Leung F, Kulasingam V, Diamandis EP, Hoon DS, Kinzler K, Pantel K, Alix-Panabières C. Circulating tumor DNA as a cancer biomarker: fact or fiction? Clin Chem. 2016;62(8):1054–60.PubMedPubMedCentralCrossRef

go back to reference Sumbal S, Javed A, Afroze B, Zulfiqar HF, Javed F, Noreen S, Ijaz B. Circulating tumor DNA in blood: future genomic biomarkers for cancer detection. Exp Hematol. 2018;65:17–28.PubMedCrossRef Sumbal S, Javed A, Afroze B, Zulfiqar HF, Javed F, Noreen S, Ijaz B. Circulating tumor DNA in blood: future genomic biomarkers for cancer detection. Exp Hematol. 2018;65:17–28.PubMedCrossRef

go back to reference Han X, Wang J, Sun Y. Circulating tumor DNA as biomarkers for cancerdetection. Genomics Proteomics Bioinf. 2017;15(2):59–72.CrossRef Han X, Wang J, Sun Y. Circulating tumor DNA as biomarkers for cancerdetection. Genomics Proteomics Bioinf. 2017;15(2):59–72.CrossRef

go back to reference Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–65.PubMed Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–65.PubMed

go back to reference Mouliere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, Molina F, Gongora C, Thierry AR. High fragmentation characterizes tumour-derived circulating DNA. PLoS ONE. 2011;6(9):e23418.PubMedPubMedCentralCrossRef Mouliere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, Molina F, Gongora C, Thierry AR. High fragmentation characterizes tumour-derived circulating DNA. PLoS ONE. 2011;6(9):e23418.PubMedPubMedCentralCrossRef

go back to reference Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann Oncol. 2014;25(12):2304–13.PubMedCrossRef Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann Oncol. 2014;25(12):2304–13.PubMedCrossRef

go back to reference Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med. 2010;10(2):123–32.PubMedPubMedCentralCrossRef Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med. 2010;10(2):123–32.PubMedPubMedCentralCrossRef

go back to reference De Rubis G, Krishnan SR, Bebawy M. Circulating tumor DNA—current state of play and future perspectives. Pharmacol Res. 2018;136:35–44.PubMedCrossRef De Rubis G, Krishnan SR, Bebawy M. Circulating tumor DNA—current state of play and future perspectives. Pharmacol Res. 2018;136:35–44.PubMedCrossRef

go back to reference Khakoo S, Georgiou A, Gerlinger M, Cunningham D, Starling N. Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. Crit Rev Oncol Hematol. 2018;122:72–82.PubMedCrossRef Khakoo S, Georgiou A, Gerlinger M, Cunningham D, Starling N. Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. Crit Rev Oncol Hematol. 2018;122:72–82.PubMedCrossRef

go back to reference Vendrell JA, Mau-Them FT, Beganton B, Godreuil S, Coopman P, Solassol J. Circulating cell free tumor DNA detection as a routine tool for lung cancer patient management. Int J Mol Sci. 2017;18(2):E264.PubMedCrossRef Vendrell JA, Mau-Them FT, Beganton B, Godreuil S, Coopman P, Solassol J. Circulating cell free tumor DNA detection as a routine tool for lung cancer patient management. Int J Mol Sci. 2017;18(2):E264.PubMedCrossRef

go back to reference Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472–84.PubMedCrossRef Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472–84.PubMedCrossRef

go back to reference Rickel K, Fang F, Tao J. Molecular genetics of OS. Bone. 2017;102:69–79.PubMedCrossRef Rickel K, Fang F, Tao J. Molecular genetics of OS. Bone. 2017;102:69–79.PubMedCrossRef

go back to reference Barris DM, Weiner SB, Dubin RA, Fremed M, Zhang X, Piperdi S, Zhang W, Maqbool S, Gill J, Roth M, Hoang B, Geller D, Gorlick R, Weiser DA. Detection of circulating tumor DNA in patients with OS. Oncotarget. 2018;9(16):12695–704.PubMedPubMedCentralCrossRef Barris DM, Weiner SB, Dubin RA, Fremed M, Zhang X, Piperdi S, Zhang W, Maqbool S, Gill J, Roth M, Hoang B, Geller D, Gorlick R, Weiser DA. Detection of circulating tumor DNA in patients with OS. Oncotarget. 2018;9(16):12695–704.PubMedPubMedCentralCrossRef

go back to reference Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and OS: a report from the Children’s Oncology Group. Br J Cancer. 2018. https://doi.org/10.1038/s41416-018-0212-9 (Epub ahead of print).CrossRefPubMedPubMedCentral Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and OS: a report from the Children’s Oncology Group. Br J Cancer. 2018. https://​doi.​org/​10.​1038/​s41416-018-0212-9 (Epub ahead of print).CrossRefPubMedPubMedCentral

go back to reference Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O’Connor EP, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson M. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8(1):1324.PubMedPubMedCentralCrossRef Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O’Connor EP, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson M. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8(1):1324.PubMedPubMedCentralCrossRef

go back to reference Chang L, Asatrian G, Dry SM, James AW. Circulating tumor cells in sarcomas: a brief review. Med Oncol. 2015;32(1):430.PubMedCrossRef Chang L, Asatrian G, Dry SM, James AW. Circulating tumor cells in sarcomas: a brief review. Med Oncol. 2015;32(1):430.PubMedCrossRef

go back to reference Benini S, Gamberi G, Cocchi S, Garbetta J, Alberti L, Righi A, Gambarotti M, Picci P, Ferrari S. Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients. Cancer Manag Res. 2018;10:49–60.PubMedPubMedCentralCrossRef Benini S, Gamberi G, Cocchi S, Garbetta J, Alberti L, Righi A, Gambarotti M, Picci P, Ferrari S. Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients. Cancer Manag Res. 2018;10:49–60.PubMedPubMedCentralCrossRef

go back to reference Heymann D, Rédini F. Targeted therapies for bone sarcomas. Bonekey Rep. 2013;2:378.PubMedPubMedCentralCrossRef Heymann D, Rédini F. Targeted therapies for bone sarcomas. Bonekey Rep. 2013;2:378.PubMedPubMedCentralCrossRef

go back to reference DeRenzo C, Gottschalk S. Genetically modified T-cell therapy for OS. Adv Exp Med Biol. 2014;804:323–40.PubMedPubMedCentralCrossRef DeRenzo C, Gottschalk S. Genetically modified T-cell therapy for OS. Adv Exp Med Biol. 2014;804:323–40.PubMedPubMedCentralCrossRef

go back to reference Tarek N, Lee DA. Natural killer cells for OS. Adv Exp Med Biol. 2014;804:341–53.PubMedCrossRef Tarek N, Lee DA. Natural killer cells for OS. Adv Exp Med Biol. 2014;804:341–53.PubMedCrossRef

go back to reference Kawano M, Itonaga I, Iwasaki T, Tsuchiya H, Tsumura H. Anti-TGF-β antibody combined with dendritic cells produces antitumor effects in OS. Clin Orthop Relat Res. 2012;470(8):2288–94.PubMedPubMedCentralCrossRef Kawano M, Itonaga I, Iwasaki T, Tsuchiya H, Tsumura H. Anti-TGF-β antibody combined with dendritic cells produces antitumor effects in OS. Clin Orthop Relat Res. 2012;470(8):2288–94.PubMedPubMedCentralCrossRef

go back to reference Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling—are we there yet? Nat Rev Drug Discov. 2014;13(5):357–78.PubMedCrossRef Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling—are we there yet? Nat Rev Drug Discov. 2014;13(5):357–78.PubMedCrossRef

go back to reference Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions Nat. Rev Cancer. 2008;8(10):755–68.PubMedCrossRef Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions Nat. Rev Cancer. 2008;8(10):755–68.PubMedCrossRef

go back to reference Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008;99(1):100–9.PubMedPubMedCentralCrossRef Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008;99(1):100–9.PubMedPubMedCentralCrossRef

go back to reference Mallinger S, Crumpler M, Pichowicz D, et al. Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. J Med Chem. 2015;58(4):1717–35.PubMedPubMedCentralCrossRef Mallinger S, Crumpler M, Pichowicz D, et al. Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. J Med Chem. 2015;58(4):1717–35.PubMedPubMedCentralCrossRef

go back to reference Harwood JL, Alexander JH, Mayerson JL, Scharschmidt TJ. Targeted chemotherapy in bone and soft-tissue sarcoma. Orthop Clin North Am. 2015;46(4):587–608.PubMedCrossRef Harwood JL, Alexander JH, Mayerson JL, Scharschmidt TJ. Targeted chemotherapy in bone and soft-tissue sarcoma. Orthop Clin North Am. 2015;46(4):587–608.PubMedCrossRef

go back to reference Chang Y, Zhao Y, Zhan H, Wei X, Liu T, Zheng B. Bufalin inhibits the differentiation and proliferation of human osteosarcoma cell line hMG63-derived cancer stem cells. Tumour Biol. 2014;35(2):1075–82.PubMedCrossRef Chang Y, Zhao Y, Zhan H, Wei X, Liu T, Zheng B. Bufalin inhibits the differentiation and proliferation of human osteosarcoma cell line hMG63-derived cancer stem cells. Tumour Biol. 2014;35(2):1075–82.PubMedCrossRef

go back to reference Chang Y, Zhao Y, Gu W, Cao Y, Wang S, Pang J. Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through Mir-148a. Cell Physiol Biochem. 2015;36(3):1186–96.PubMedCrossRef Chang Y, Zhao Y, Gu W, Cao Y, Wang S, Pang J. Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through Mir-148a. Cell Physiol Biochem. 2015;36(3):1186–96.PubMedCrossRef

go back to reference Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658.PubMedPubMedCentralCrossRef Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658.PubMedPubMedCentralCrossRef

go back to reference Zhang Y, Liu L, Li F, Wu T, Jiang H, Jiang X, Du X, Wang Y. salinomycin exerts anticancer effects on PC-3 Cells and PC-3-derived cancer stem cells in vitro and in vivo. Biomed Res Int. 2017;2017:4101653.PubMedPubMedCentral Zhang Y, Liu L, Li F, Wu T, Jiang H, Jiang X, Du X, Wang Y. salinomycin exerts anticancer effects on PC-3 Cells and PC-3-derived cancer stem cells in vitro and in vivo. Biomed Res Int. 2017;2017:4101653.PubMedPubMedCentral

go back to reference Jiang J, Li H, Qaed E. Salinomycin, as an autophagy modulator—a new avenue to anticancer: a review. J Exp Clin Cancer Res. 2018;37(1):26.PubMedPubMedCentralCrossRef Jiang J, Li H, Qaed E. Salinomycin, as an autophagy modulator—a new avenue to anticancer: a review. J Exp Clin Cancer Res. 2018;37(1):26.PubMedPubMedCentralCrossRef

go back to reference Dewangan J, Srivastava S, Rath SK. Salinomycin: a new paradigm in cancer therapy. Tumour Biol. 2017;39(3):1010428317695035.PubMedCrossRef Dewangan J, Srivastava S, Rath SK. Salinomycin: a new paradigm in cancer therapy. Tumour Biol. 2017;39(3):1010428317695035.PubMedCrossRef

go back to reference Qu H, Xue Y, Lian W, Wang C, He J, Fu Q, Zhong L, Lin N, Lai L, Ye Z, Wang Q. Melatonin inhibits OS stem cells by suppressing SOX9-mediated signaling. Life Sci. 2018;207:253–64.PubMedCrossRef Qu H, Xue Y, Lian W, Wang C, He J, Fu Q, Zhong L, Lin N, Lai L, Ye Z, Wang Q. Melatonin inhibits OS stem cells by suppressing SOX9-mediated signaling. Life Sci. 2018;207:253–64.PubMedCrossRef

go back to reference Huynh DL, Sharma N, Singh AK, Singh Sodhi S, Zhang JJ, Mongre RK, Ghosh M, Kim N, Park YH, Jeong DK. Anti-tumor activity of wogonin, an extract from Scutellaria baicalensis, through regulating different signaling pathways. Chin J Nat Med. 2017;15(1):15–40.PubMed Huynh DL, Sharma N, Singh AK, Singh Sodhi S, Zhang JJ, Mongre RK, Ghosh M, Kim N, Park YH, Jeong DK. Anti-tumor activity of wogonin, an extract from Scutellaria baicalensis, through regulating different signaling pathways. Chin J Nat Med. 2017;15(1):15–40.PubMed

go back to reference Huynh DL, Kwon T, Zhang JJ, Sharma N, Gera M, Ghosh M, Kim N, Kim Cho S, Lee DS, Park YH, Jeong DK. Wogonin suppresses stem cell-like traits of CD133 positive OS cell via inhibiting matrix metallopeptidase-9 expression. BMC Complement Altern Med. 2017;17:304.PubMedPubMedCentralCrossRef Huynh DL, Kwon T, Zhang JJ, Sharma N, Gera M, Ghosh M, Kim N, Kim Cho S, Lee DS, Park YH, Jeong DK. Wogonin suppresses stem cell-like traits of CD133 positive OS cell via inhibiting matrix metallopeptidase-9 expression. BMC Complement Altern Med. 2017;17:304.PubMedPubMedCentralCrossRef

go back to reference Li Y, Zhang J, Ma D, Zhang L, Si M, Yin H, Li J. Curcumin inhibits proliferation and invasion of OS cells through inactivation of Notch-1 signaling. FEBS J. 2012;279(12):2247–59.PubMedCrossRef Li Y, Zhang J, Ma D, Zhang L, Si M, Yin H, Li J. Curcumin inhibits proliferation and invasion of OS cells through inactivation of Notch-1 signaling. FEBS J. 2012;279(12):2247–59.PubMedCrossRef

go back to reference Aziz MNM, Hussin Y, Che Rahim NF, Nordin N, Mohamad NE, Yeap SK, Yong CY, Masarudin MJ, Cheah YK, Abu N, Akhtar MN, Alitheen NB. Curcumin analog DK1 induces apoptosis in human OS Cells in vitro through mitochondria-dependent signaling pathway. Molecules. 2018;23(1):75.CrossRefPubMedCentral Aziz MNM, Hussin Y, Che Rahim NF, Nordin N, Mohamad NE, Yeap SK, Yong CY, Masarudin MJ, Cheah YK, Abu N, Akhtar MN, Alitheen NB. Curcumin analog DK1 induces apoptosis in human OS Cells in vitro through mitochondria-dependent signaling pathway. Molecules. 2018;23(1):75.CrossRefPubMedCentral

go back to reference Peng SF, Lee CY, Hour MJ, Tsai SC, Kuo DH, Chen FA. Curcumin-loaded nanoparticles enhance apoptotic cell death of U2OS human OS cells through the Akt-Bad signaling pathway. Int J Oncol. 2014;44(1):238–46.PubMedCrossRef Peng SF, Lee CY, Hour MJ, Tsai SC, Kuo DH, Chen FA. Curcumin-loaded nanoparticles enhance apoptotic cell death of U2OS human OS cells through the Akt-Bad signaling pathway. Int J Oncol. 2014;44(1):238–46.PubMedCrossRef

go back to reference Kwon T, Chandimali N, Huynh DL, Zhang JJ, Kim N, Bak Y, Yoon DY, Yu DY, Lee JC, Gera M, Ghosh M, Park YH, Jeong DK. BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells. Cell Death Dis. 2018;9(2):244.PubMedPubMedCentralCrossRef Kwon T, Chandimali N, Huynh DL, Zhang JJ, Kim N, Bak Y, Yoon DY, Yu DY, Lee JC, Gera M, Ghosh M, Park YH, Jeong DK. BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells. Cell Death Dis. 2018;9(2):244.PubMedPubMedCentralCrossRef

go back to reference Di Pompo G, Salerno M, Rotili D, Valente S, Zwergel C, Avnet S, Lattanzi G, Baldini N, Mai A. Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells. J Med Chem. 2015;58(9):4073–9.PubMedCrossRef Di Pompo G, Salerno M, Rotili D, Valente S, Zwergel C, Avnet S, Lattanzi G, Baldini N, Mai A. Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells. J Med Chem. 2015;58(9):4073–9.PubMedCrossRef

go back to reference Chen F, Zeng Y, Qi X, Chen Y, Ge Z, Jiang Z, Zhang X, Dong Y, Chen H, Yu Z. Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells. Nanomedicine. 2018;14(7):2115–27.PubMedCrossRef Chen F, Zeng Y, Qi X, Chen Y, Ge Z, Jiang Z, Zhang X, Dong Y, Chen H, Yu Z. Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells. Nanomedicine. 2018;14(7):2115–27.PubMedCrossRef

go back to reference Ni M, Xiong M, Zhang X, Cai G, Chen H, Zeng Q, Yu Z. Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells. Int J Nanomedicine. 2015;10:2537–54.PubMedPubMedCentralCrossRef Ni M, Xiong M, Zhang X, Cai G, Chen H, Zeng Q, Yu Z. Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133⁺ osteosarcoma cancer stem cells. Int J Nanomedicine. 2015;10:2537–54.PubMedPubMedCentralCrossRef

go back to reference Yu X, Zhang X, Zhang Z, Lin Y, Wen Y, Chen Y, Wang W, Zhang L. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience. Cancer Commun (Lond). 2018;38(1):51.PubMedPubMedCentralCrossRef Yu X, Zhang X, Zhang Z, Lin Y, Wen Y, Chen Y, Wang W, Zhang L. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience. Cancer Commun (Lond). 2018;38(1):51.PubMedPubMedCentralCrossRef

go back to reference Tirino V, La Noce M, Paino F, Mele L, Desiderio V, Papaccio G. Valproic acid and 5-azacytidine promote an increase of stemness phenotype in human osteosarcomas. Italian J Anat Embryol. 2016;121(1):48. Tirino V, La Noce M, Paino F, Mele L, Desiderio V, Papaccio G. Valproic acid and 5-azacytidine promote an increase of stemness phenotype in human osteosarcomas. Italian J Anat Embryol. 2016;121(1):48.